Graffinity and Amgen enter into drug discovery research agreement
28-Feb-2007
Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Amgen. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a broad range of drug targets. Amgen will gain access to Graffinity's proprietary fragment-based drug discovery technology which uses chemical microarrays to screen for small molecule fragments that bind to a variety of drug targets which play a key role in major human diseases. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Intertek Acquires American Analytical Chemistry Laboratories Corp
New imaging analysis method revolutionizes the diagnosis of head and neck tumors
Significant breakthrough in the chemistry of fluorinated compounds - Overcoming the “Fluoro Wall”: Researchers observe tunneling effect of heavy atoms for the first time
X-rays reveal how glasses lose their stability - PETRA III experiment shows how atoms in glass behave as weaknesses appear
Earlier unknown molecular-level mechanism may contribute to the growth rate of breast cancer
PET points to tau protein as leading culprit in Alzheimer's
Syrris Establish Japanese Subsidiary Office - Syrris Expand Global Sales Network to Match Growing Demand in the Far East
Sartorius reviews fiscal 2008 - Different outlook for the two Group divisions
SGS Australia opens new Sydney Laboratory for Environmental Testing
Thermo Fisher Scientific Announces Partnership with Megaware to Deliver New Bioequivalence Solution
Neandertal genome project reaches its goal - High-quality Neandertal genome provides novel insights into human origins
